These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25096666)

  • 1. The cardiovascular safety of azithromycin.
    Juurlink DN
    CMAJ; 2014 Oct; 186(15):1127-8. PubMed ID: 25096666
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term macrolide therapy in chronic obstructive pulmonary disease.
    Parameswaran GI; Sethi S
    CMAJ; 2014 Oct; 186(15):1148-52. PubMed ID: 25096664
    [No Abstract]   [Full Text] [Related]  

  • 3. [COPD and bacterial colonization: therapeutic implications].
    Gómez J; Baños V; García Martín E
    Rev Esp Quimioter; 2005 Jun; 18(2):187-91. PubMed ID: 16130042
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antimicrobial therapy in exacerbated chronic obstructive pulmonary disease].
    Alvarez F; Bouza E; García-Rodríguez JA; Mayer MA; Mensa J; Monsó E; Nodar E; Picazo JJ; Sobradillo V; Torres A;
    Arch Bronconeumol; 2002 Feb; 38(2):81-9. PubMed ID: 11844440
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-inflammatory effect of prophylactic macrolides on children with chronic lung disease: a protocol for a double-blinded randomised controlled trial.
    Mosquera RA; Gomez-Rubio AM; Harris T; Yadav A; McBeth K; Gonzales T; Jon C; Stark J; Avritscher E; Pedroza C; Smith K; Colasurdo G; Wootton S; Piedra P; Tyson JE; Samuels C
    BMJ Open; 2016 Sep; 6(9):e012060. PubMed ID: 27638496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic uses of the macrolides].
    Mihălţan F
    Pneumologia; 2004; 53(3):100-4. PubMed ID: 16108157
    [No Abstract]   [Full Text] [Related]  

  • 7. [Acute respiratory tract infection in chronically ill patients. germ spectrum different than in healthy persons].
    MMW Fortschr Med; 2003 Dec; 145(49):61. PubMed ID: 14964003
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.
    Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J
    Trials; 2012 Jun; 13():82. PubMed ID: 22682323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for lower respiratory tract infections.
    Liapikou A; Torres A
    Expert Opin Pharmacother; 2014 Nov; 15(16):2307-18. PubMed ID: 25216725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rising to the challenge of resistance: a case study-based discussion.
    Housset B
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S11-6. PubMed ID: 17307651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolides in dermatology.
    Scheinfeld NS; Tutrone WD; Torres O; Weinberg JM
    Dis Mon; 2004 Jul; 50(7):350-68. PubMed ID: 15280867
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which patients with respiratory disease need long-term azithromycin?
    Alchakaki A; Cramer C; Patterson A; Soubani AO
    Cleve Clin J Med; 2017 Oct; 84(10):755-758. PubMed ID: 28985171
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin.
    Djamin RS; Talman S; Schrauwen EJA; von Wintersdorff CJH; Wolffs PF; Savelkoul PHM; Uzun S; Kerstens R; van der Eerden MM; Kluytmans JAJW
    Antimicrob Resist Infect Control; 2020 Jul; 9(1):116. PubMed ID: 32723393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term macrolide treatment for chronic respiratory disease.
    Spagnolo P; Fabbri LM; Bush A
    Eur Respir J; 2013 Jul; 42(1):239-51. PubMed ID: 23180583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of macrolides in lower respiratory tract infections.
    Dietrich ES; Voegele T; Frank U; Daschner FD
    Ann Pharmacother; 1999 Oct; 33(10):1125-6. PubMed ID: 10534230
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventing COPD exacerbations: budget impact of a respiratory day hospital and long-term azithromycin therapy.
    Pomares Amigó X; Montón Soler C
    Respir Med; 2014 Jul; 108(7):1064. PubMed ID: 24833008
    [No Abstract]   [Full Text] [Related]  

  • 20. [Guideline for treatment respiratory infections].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2009 Dec; 32(12):437. PubMed ID: 20088344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.